Navigation Links
TorreyPines Therapeutics to Present at ThinkEquity's G5 Conference
Date:9/11/2007

LA JOLLA, Calif., Sept. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer of TorreyPines, will present at ThinkEquity's G5 Conference in San Francisco on Tuesday, September 18th at 2:30 p.m., local time (5:30 p.m., Eastern).

A webcast of Dr. Kurtz's presentation will be available live. You can access the webcast at: http://www.torreypinestherapeutics.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...wire/ -- Spectrum Blue Steel is emerging as one of... planet. Through the efforts of True Green Energy ...ing Specialist Leroy Johnston, who has been in the... Spectrum Blue Steel is light years ahead of every...ngs because of the bi products recovered by using ...
(Date:12/2/2009)...wswire/ -- Nearly 600 medical research executives,...ened to explore novel development approaches and i...tnering for Cures meeting. ,, FasterCures, ...e, convened Partnering for Cures to facilitate m...ific discovery into an accessible therapy. This e...
(Date:12/2/2009)... , - "Bolstering Biodiver...,, Coinciding with the International Year o...c is hosting an international conference in Librev...al resources in Africa. The,conference will be att...scientific experts, private companies, representat...
(Date:12/2/2009)...e/ -- S*BIO Pte Ltd today announced data presentat...The American Society of Hematology 51st Annual Mee...l be presented on the clinical results from the Ph...s safety, tolerability and pharmacokinetic/pharmac...om 100 to 600 mg. These doses were administered on...
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...8 ,Neurobiological Technologies, Inc. (NTI(R)) (Na...il 1, 2008, Matthew M. Loar has been appointed Chi...e Company,s headquarters in,Emeryville. Mr. Loar j...ved,as Chief Financial Officer since 2006., "Matt...ficer, and we,will look to his expertise to help g...
...Solutions Holdings PLC,("Plethora", AIM: PLE), the...t and management of urological disorders, today an...t financing agreement with Paul Capital,Healthcare... to $28 million,in cash with $15 million payable u... commercial sale of PSD502 (PLE,s development stag...
... Rx,Corporation (OTC Bulletin Board: PMQC, PMQCU, ...cy services, announced today that it has postponed...lts and discuss 2008 outlook,that was originally s...onal,details about the timing of the 2007 financia...ce call will be forthcoming shortly., About Chem ...
Other Biology Technology:Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 2Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 4Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results 2
(Date:12/4/2009)...electroencephalogram (EEG) is widely used by physi...o diagnose neurological disorders. However, it has...n the head give an exact view of what is happening...stitute for Biological Cybernetics in Tbingen, Ger...tivity generated within the brain to that measured...
(Date:12/4/2009)...major discovery is challenging accepted thinking a...ated with diseases such as Alzheimer,s and Parkins...rapeutics. , It was believed that amyloid fibril...imes known as fibres - are inert, but that there m...n damage cells and cause disease. , But in a pa...
(Date:12/3/2009)...r ability to learn new information and adapt to ch...in lifelong memories, appears to lie in the minute...g to a new study by NYU Langone Medicine Center re... in the journal Nature . , The scientists, led...iology and neuroscience at NYU School of Medicine,...
Breaking Biology News(10 mins):How to read brain activity? 2New therapy targets for amyloid disease 2Lifelong memories linked to stable nerve connections 2Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 1Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 2Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline 51037 1Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline 51037 2Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 51032 1Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 51032 2
...dicine researchers have discovered how new neurons...o regions of the brain where they can replace old ...cell therapies can be specifically targeted to bra...or by stroke. , Associate Professor Qun-Yong Zhou ...ent of Pharmacology have identified a protein that...
...ton University in St. Louis has shown that for som...exual organs, and actually choose them for mating.... sex organ, called a gonopodium. These fish out-co... environment because they have a faster burst spee...ut because the size of their organ slows them down...
... world are breathing a sigh of relief, as they no ...atural disease-fighting substances. Scientists rec...emnii, which lives symbiotically inside the sea sq...compounds that may one day be used in cancer treat...uld not successfully cultivate Prochloron in the l...
Other Biology News:Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2Certain fish have a special mating preference 2Certain fish have a special mating preference 3Certain fish have a special mating preference 4
Stat-Pack Aldolase Controls from Caldon Biotech, Inc.
EDTA, 0.5 M solution from GE Healthcare, formerly Amersham Biosciences
Human VEGFR2 (KDR), phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Mouse sTNF RII / TNFRSF1B from R&D Systems
Biology Products: